Theranostics Health (TH) is a privately held company founded in 2006. Its proprietary technology platform includes fixative reagents, Laser Capture Microdissection (LCM), and Reverse Phase Protein Microarray (RPMA). TH’s proprietary fixatives are developed to both preserve cell morphology and fix the state of cellular activities for molecular analysis. LCM is used to isolate specific cell populations from many different types of cells usually present in a clinical biopsy. Therefore, information derived from subsequent molecular assays is specific to that cell population. RPMA enables sensitive, quantitative, calibrated, multiplexed analysis of cellular proteins from a limited amount of starting materials, such as clinical specimens. TH has an exclusive license from the National Institute of Health (NIH) to commercialize microdissection, including LCM, combined with protein analysis for cancer diagnostics and companion diagnostics. While providing research and development services to pharmaceutical companies and academic institutions for efficient and effective target discovery and drug development, TH is developing clinical tests, enabling physicians to tailor optimized therapies for patients based on the biomarker profile of each patient’s disease specimen. The technology, developed by the company’s scientific co-founders, Drs. Emanuel Petricoin and Lance Liotta, was first published in 2001 and in the past 2 years has been used in studies published in more than 50 peer-reviewed journals and presentations. TH’s technology was also successfully used in NCI-sponsored clinical trials.